What is dificid, and how does it work?
Dificid, also known as fidaxomicin, is an antibiotic medication used to treat Clostridioides difficile (C. diff) infections in adults [1]. It belongs to the class of macrolide antibiotics. Dificid works by inhibiting bacterial protein synthesis, ultimately leading to the death of C. diff bacteria.
Dificid and diarrhea: is there a connection?
The mechanism of action of Dificid is designed to target and eliminate C. diff bacteria, which can cause symptoms such as diarrhea [2]. However, as the body heals from the C. diff infection, it is not uncommon for patients to experience a temporary increase in diarrhea or watery stools.
Why does Dificid sometimes cause diarrhea?
Research suggests that the antibiotic properties of Dificid can disrupt the balance of gut bacteria, leading to changes in the gut microbiome. This imbalance can cause symptoms like diarrhea, abdominal pain, and changes in bowel habit [3]. The severity and duration of these symptoms typically subside as treatment progresses.
Duration of Dificid treatment and diarrhea side effects
Typically, patients taking Dificid for C. diff infections experience diarrhea within the first few days of treatment. However, studies have shown that symptoms like diarrhea resolve in most patients by the end of the 10-day treatment course [4].
Alternatives and considerations for patients taking Dificid
For some patients, alternative medications like vancomycin may be prescribed, particularly for those with a history of Dificid side effects. It is essential to discuss individual health concerns with a healthcare professional to determine the best course of treatment.
Sources:
[1] Dificid [package insert]. Merck & Co, Inc. https://www.drugs.com/pro/dificid.html
[2] Gorbach, S. L. (2013). Clostridium difficile Infection: New Insights in Diagnosis and Treatment. Journal of Infection, 66(2), 131–138.
[3] Gerding, D. N. (2014). Current Treatment Options for Clostridium difficile Infection. Current Infectious Disease Reports, 16(6), 453.
[4] Louie, T. J. (2011). Fidaxomicin versus Vancomycin for Initial Treatment of Clostridium difficile Infection: A Randomized Controlled Trial. Clinical Infectious Diseases, 52(4), 434–441.